BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 37675821)

  • 21. Spinal cord anaplastic astrocytoma with BRAF V600E mutation: A case report and review of literature.
    Takamiya S; Hatanaka KC; Ishi Y; Seki T; Yamaguchi S
    Neuropathology; 2020 Jun; 40(3):275-279. PubMed ID: 31986557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Establishment and application of a novel patient-derived KIAA1549:BRAF-driven pediatric pilocytic astrocytoma model for preclinical drug testing.
    Selt F; Hohloch J; Hielscher T; Sahm F; Capper D; Korshunov A; Usta D; Brabetz S; Ridinger J; Ecker J; Oehme I; Gronych J; Marquardt V; Pauck D; Bächli H; Stiles CD; von Deimling A; Remke M; Schuhmann MU; Pfister SM; Brummer T; Jones DT; Witt O; Milde T
    Oncotarget; 2017 Feb; 8(7):11460-11479. PubMed ID: 28002790
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Oncogenic RAF1 rearrangement and a novel BRAF mutation as alternatives to KIAA1549:BRAF fusion in activating the MAPK pathway in pilocytic astrocytoma.
    Jones DT; Kocialkowski S; Liu L; Pearson DM; Ichimura K; Collins VP
    Oncogene; 2009 May; 28(20):2119-23. PubMed ID: 19363522
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeted therapy for BRAFV600E malignant astrocytoma.
    Nicolaides TP; Li H; Solomon DA; Hariono S; Hashizume R; Barkovich K; Baker SJ; Paugh BS; Jones C; Forshew T; Hindley GF; Hodgson JG; Kim JS; Rowitch DH; Weiss WA; Waldman TA; James CD
    Clin Cancer Res; 2011 Dec; 17(24):7595-604. PubMed ID: 22038996
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Somatic BRAF c.1799T>A p.V600E Mosaicism syndrome characterized by a linear syringocystadenoma papilliferum, anaplastic astrocytoma, and ocular abnormalities.
    Watanabe Y; Shido K; Niihori T; Niizuma H; Katata Y; Iizuka C; Oba D; Moriya K; Saito-Nanjo Y; Onuma M; Rikiishi T; Sasahara Y; Watanabe M; Aiba S; Saito R; Sonoda Y; Tominaga T; Aoki Y; Kure S
    Am J Med Genet A; 2016 Jan; 170A(1):189-94. PubMed ID: 26360803
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
    Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
    Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
    [TBL] [Abstract][Full Text] [Related]  

  • 27. V600E BRAF mutation in pilocytic astrocytoma is associated with a more diffuse growth pattern but does not confer a more aggressive clinical behavior.
    Bannykh SI; Mirocha J; Nuno M; Lopategui J; Kandala G
    Clin Neuropathol; 2014; 33(6):388-98. PubMed ID: 25066317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma.
    Schindler G; Capper D; Meyer J; Janzarik W; Omran H; Herold-Mende C; Schmieder K; Wesseling P; Mawrin C; Hasselblatt M; Louis DN; Korshunov A; Pfister S; Hartmann C; Paulus W; Reifenberger G; von Deimling A
    Acta Neuropathol; 2011 Mar; 121(3):397-405. PubMed ID: 21274720
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma.
    Korshunov A; Meyer J; Capper D; Christians A; Remke M; Witt H; Pfister S; von Deimling A; Hartmann C
    Acta Neuropathol; 2009 Sep; 118(3):401-5. PubMed ID: 19543740
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Epithelioid glioblastoma arising from pleomorphic xanthoastrocytoma with the BRAF V600E mutation.
    Tanaka S; Nakada M; Nobusawa S; Suzuki SO; Sabit H; Miyashita K; Hayashi Y
    Brain Tumor Pathol; 2014 Jul; 31(3):172-6. PubMed ID: 24894018
    [TBL] [Abstract][Full Text] [Related]  

  • 31. An activated mutant BRAF kinase domain is sufficient to induce pilocytic astrocytoma in mice.
    Gronych J; Korshunov A; Bageritz J; Milde T; Jugold M; Hambardzumyan D; Remke M; Hartmann C; Witt H; Jones DT; Witt O; Heiland S; Bendszus M; Holland EC; Pfister S; Lichter P
    J Clin Invest; 2011 Apr; 121(4):1344-8. PubMed ID: 21403401
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rare adult pilocytic astrocytoma of the septum pellucidum with novel RIN2::BRAF fusion.
    Liu X; Dai X; Dai C; Zhu Q; Chen A; Chen Y; Chen N; Chen P; Rong R; Shi C; Xiao S; Dong J
    Virchows Arch; 2023 Feb; 482(2):445-450. PubMed ID: 36520196
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Present and potential future adjuvant issues in high-grade astrocytic glioma treatment.
    Lefranc F; Rynkowski M; DeWitte O; Kiss R
    Adv Tech Stand Neurosurg; 2009; 34():3-35. PubMed ID: 19368079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Surgical and molecular considerations in the treatment of pediatric thalamopeduncular tumors.
    Lee RP; Foster KA; Lillard JC; Klimo P; Ellison DW; Orr B; Boop FA
    J Neurosurg Pediatr; 2017 Sep; 20(3):247-255. PubMed ID: 28686121
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Molecular characterization of disseminated pilocytic astrocytomas.
    Gessi M; Engels AC; Lambert S; Rothämel T; von Hornstein S; Collins VP; Denkhaus D; Gnekow A; Pietsch T
    Neuropathol Appl Neurobiol; 2016 Apr; 42(3):273-8. PubMed ID: 26084390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical neuropathology practice news 2-2012: BRAF V600E testing.
    Capper D; Berghoff AS; von Deimling A; Preusser M
    Clin Neuropathol; 2012; 31(2):64-6. PubMed ID: 22385786
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Practical molecular pathologic diagnosis of pilocytic astrocytomas.
    Reis GF; Tihan T
    Surg Pathol Clin; 2015 Mar; 8(1):63-71. PubMed ID: 25783822
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations.
    Reinhardt A; Stichel D; Schrimpf D; Sahm F; Korshunov A; Reuss DE; Koelsche C; Huang K; Wefers AK; Hovestadt V; Sill M; Gramatzki D; Felsberg J; Reifenberger G; Koch A; Thomale UW; Becker A; Hans VH; Prinz M; Staszewski O; Acker T; Dohmen H; Hartmann C; Mueller W; Tuffaha MSA; Paulus W; Heß K; Brokinkel B; Schittenhelm J; Monoranu CM; Kessler AF; Loehr M; Buslei R; Deckert M; Mawrin C; Kohlhof P; Hewer E; Olar A; Rodriguez FJ; Giannini C; NageswaraRao AA; Tabori U; Nunes NM; Weller M; Pohl U; Jaunmuktane Z; Brandner S; Unterberg A; Hänggi D; Platten M; Pfister SM; Wick W; Herold-Mende C; Jones DTW; von Deimling A; Capper D
    Acta Neuropathol; 2018 Aug; 136(2):273-291. PubMed ID: 29564591
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pleomorphic xanthoastrocytoma, anaplastic pleomorphic xanthoastrocytoma, and epithelioid glioblastoma: Case series with clinical characteristics, molecular features and progression relationship.
    Lin Z; Yang R; Zheng H; Li Z; Yi G; Wu Q; Yang C; Huang G
    Clin Neurol Neurosurg; 2022 Oct; 221():107379. PubMed ID: 35932588
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of MEK confers hypersensitivity to X-radiation in the context of BRAF mutation in a model of childhood astrocytoma.
    Studebaker A; Bondra K; Seum S; Shen C; Phelps DA; Chronowski C; Leasure J; Smith PD; Kurmasheva RT; Mo X; Fouladi M; Houghton PJ
    Pediatr Blood Cancer; 2015 Oct; 62(10):1768-74. PubMed ID: 25981859
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.